



**Half** Yearly  
**Report**  
2 0 0 5



**BEXIMCO PHARMACEUTICALS LTD.**

## BEXIMCO PHARMACEUTICALS LTD. STATEMENT OF THE CHIEF EXECUTIVE OFFICER

*Dear Shareholder*

### Summarized financial results

BPL continues to perform strongly during the half-year ended 30 June 2005. Key financial results are summarized below:-

	2005	2004	Growth
	Tk million	Tk million	%
Turnover & Other Income	1,446	1,383	4.52
Gross profit	698	550	26.90
Net Profit	231	162	42.75
Earnings per share (EPS)	6.10	4.27	42.75
Net asset value per share (NAV)	100.61	96.14	4.66

During the half-year ended 30 June 2005 -

Turnover & Other Income increased by 4.52% to Tk. 1,446 million

Net profit rose by 42.75 % to Tk. 231 millions

Earnings per share (EPS) on an annualized basis was up by 42.75% to Tk. 6.10

Net asset value (NAV) per share at half-year end stood at Tk. 100.61

### Merger of Beximco Infusions with Beximco Pharma

Pursuant to an Order of the High Court Division of the Supreme Court of Bangladesh on 15 June 2005, Beximco Infusions Limited was merged with Beximco Pharmaceuticals Limited, by deemed to have been taken over the assets, liabilities, operations, licenses, rights, benefits and obligations of Beximco Infusions by Beximco Pharma with effect from 1 January 2005. Therefore, the results for the half-year ended 30 June 2005 with the corresponding figures for 2004 include the combined results of Beximco Pharma and Beximco Infusions. The merger at 4.5 (four and a half) Beximco Pharma shares for 1(one) Beximco Infusions share, yielded a capital reserve of Tk 315 million.

### Key drivers

Sales continues to remain concentrated in the domestic market. Neoceptin R, Napa, Amdocal, Bextrum, Tofen, Neofloxin, Azmasol, Ultrafen, Tycil, Filmet, Omastin, Dexaqua and Dexoride continue to be the main drivers. However, during the half-year ended 30 June 2005, BPL has launched 9 new products in the domestic market. BPL also registered a total of 47 products (including dosage forms and strengths) in a number of existing international markets and in two new international markets – Sri Lanka and Cambodia.

### Dividends

BPL held its 29th Annual General Meeting (AGM) on 2 June 2005, attended by around 8,000 shareholders, whereat 5% cash dividend and 25% stock dividend (bonus shares) were approved. The financial results for the half-year ended 30 June 2005 have considered the aforesaid declarations.

### Settlement with Shamil Bank of Bahrain EC

The company reached an out-of-court settlement with Shamil Bank of Bahrain EC, agreeing to pay the obligations within 2006. Payment has already commenced as per agreement.

### Issue of GDRs

BPL meanwhile decided to issue New Ordinary shares upto Tk 350 million for placing and offering GDRs upto GBP 30 million and to list on the Alternative Investment Market (AIM) of the London Stock Exchange (LSE). It is expected that the issue would be placed, offered and listed within September 2005.

BPL expects to achieve its planned sale and profit growth.

*Nazmul Hassan*

**Nazmul Hassan**  
Chief Executive Officer

## BEXIMCO PHARMACEUTICALS LTD.

### INCOME STATEMENT (Unaudited) For the Half-Year ended 30th June, 2005

	Taka' 000		
	Half-Year ended 30th June, 2005	Half-Year ended 30th June, 2004	Growth %
Turnover and Other Income	1,445,859	1,383,388	4.52
<b>Cost and Expenses :</b>			
Cost of Goods Sold	747,820	833,309	(10.26)
Administrative Expenses	48,720	36,011	35.29
Selling & Distribution Expenses	289,717	231,330	25.24
Finance Cost	103,347	98,766	4.64
Total Costs and Expenses	1,189,604	1,199,416	(0.82)
<b>Net Profit Before Income Tax</b>	<b>256,255</b>	<b>183,972</b>	<b>39.29</b>
Income Tax Expense	24,846	21,862	13.65
<b>Net Profit</b>	<b>Tk. 231,409</b>	<b>162,110</b>	<b>42.75</b>
Earnings Per Share (EPS)-Annualized	6.10	4.27	42.75

*Nazmul Hassan*

**Nazmul Hassan**  
Chief Executive Officer

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

# BEXIMCO PHARMACEUTICALS LTD.

## BALANCE SHEET (Unaudited)

As at 30th June, 2005

Taka' 000

	Notes	As at 30th June, 2005	As at 30th June, 2004	Growth %
<b>ASSETS</b>				
<b>Non-Current Assets</b>				
Property, Plant and Equipment		6,696,267	6,431,650	4.11
Long Term Investment		53,225	45,624	16.66
<b>Current Assets:</b>		<b>2,855,679</b>	<b>2,534,012</b>	<b>12.69</b>
Inventories		1,536,269	1,360,014	12.96
Sundry Debtors		730,291	642,706	13.63
Advances, Deposits and Pre-Payments		582,348	520,705	11.84
Cash and Cash Equivalents		6,771	10,587	(36.04)
	<b>Tk.</b>	<b>9,605,171</b>	<b>9,011,286</b>	<b>6.59</b>
<b>EQUITY AND LIABILITIES</b>				
<b>Shareholders' Equity</b>				
Share Capital	4	759,216	674,763	12.52
Share Premium		1,489,750	1,489,750	-
Capital Reserve	5	314,873	-	100.00
Reserve and Surplus		2,882,862	2,939,531	(1.93)
<b>Non-Current Liabilities</b>		<b>2,192,043</b>	<b>2,194,846</b>	<b>(0.13)</b>
<b>Current Liabilities</b>		<b>1,966,427</b>	<b>1,712,396</b>	<b>14.83</b>
Bank Loans, Overdrafts & Credits		1,569,438	1,280,255	22.59
Creditors and Accruals		396,989	432,141	(8.13)
	<b>Tk.</b>	<b>9,605,171</b>	<b>9,011,286</b>	<b>6.59</b>

*Nazmul Hassan*

**Nazmul Hassan**  
Chief Executive Officer

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

## BEXIMCO PHARMACEUTICALS LTD.

### CASH FLOW STATEMENT (Unaudited) For the Half-Year ended 30th June, 2005

Taka' 000

	Half-Year ended 30th June, 2005	Half-Year ended 30th June, 2004	Growth %
<b>Cash Flows From Operating Activities :</b>			
Collection from Turnover and other Income	1,469,513	1,358,338	8.18
Payments for Cost and Expenses	(1,225,226)	(1,235,951)	(0.87)
Income Tax Paid and/or Deducted	(11,511)	(9,331)	23.36
	<b>232,776</b>	<b>113,056</b>	<b>105.89</b>
<b>Cash Flows From Investing Activities :</b>			
Acquisition of Property, Plant & Equipment	(236,212)	(287,708)	(17.90)
Sale Proceeds of Property, Plant & Equipment	674	561	20.14
	<b>(235,538)</b>	<b>(287,147)</b>	<b>(17.97)</b>
<b>Cash Flows From Financing Activities :</b>			
Bank Loans & Overdrafts Received	6,073	194,702	(96.88)
Long Term Loan Received/(Paid)	(5,917)	(15,409)	(61.60)
Dividend Paid	(1,142)	(1,007)	13.41
	<b>(986)</b>	<b>178,286</b>	<b>(100.55)</b>
<b>Net Cash Inflows/(Outflows)</b>	<b>(3,748)</b>	<b>4,195</b>	<b>(189.34)</b>
Opening Cash and Cash Equivalents	10,519	6,393	64.54
Closing Cash and Cash Equivalents	6,771	10,587	(36.05)

*Nazmul Hassan*

**Nazmul Hassan**  
Chief Executive Officer

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**BEXIMCO PHARMACEUTICALS LTD.**  
**NOTES TO THE FINANCIAL STATEMENTS (Un-Audited)**  
**For the Half-Year ended 30th June, 2005**

**1. Status and Activities**

These half-yearly financial statements relate to Beximco Pharmaceuticals Limited, a public company incorporated in Bangladesh in 1976. The Company merged Beximco Infusions Limited, another public company on 1 July 2005, merging its assets, liabilities and operations from 1 January 2005. The principal activities of the company are manufacturing and marketing of formulation products, bulk drugs and IV fluids.

**2. Comparative Amounts**


The financial figures show the consolidated figures of Beximco Pharmaceuticals Limited and erstwhile Beximco Infusions Limited. The comparative prior period figures however do not reflect the effects of "Share Exchange" of 1 BIL share for 4.5 BPL shares; change in the accounting policies relating to "Leases" in compliance with BAS 17, "Leases" and "Deferred Tax" in compliance with BAS-12 "Income Tax".

**3. Principal Accounting Policies**

The company followed principal accounting policies (including International Accounting Standards as adopted in Bangladesh, commonly known as BAS) consistently, except that it has adopted, for the first time, BAS 17-"Leases". The company however has not yet adopted BAS 21-"The Effects of Changes in Foreign Exchange Rates" as that conflicts with the provisions of the Companies Act, 1994.

	<i>Taka in Thousand</i>	
	As at 30 June 2005	As at 30 June 2004
<b>4. Issued Share Capital</b>		
Fully paid-up shares	559,763	608,875
Bonus shares	139,941	65,888
Shares of BPL issued in exchange for shares of BIL	59,513	-
<b>Tk.</b>	<b><u>759,216</u></b>	<b><u>674,763</u></b>
<b>5. Capital Reserve</b>		
Shareholders' Equity of BIL as of 1 January 2005	336,942	-
Prior years' adjustment for Capitalization of Operating Lease	43,194	-
Cash Dividend	(5,750)	-
Shares of BPL issued in exchange for shares of BIL	(59,513)	-
<b>Tk.</b>	<b><u>314,873</u></b>	<b><u>-</u></b>

## Half Yearly Comparative Operating Results 2005 & 2004



**BEXIMCO PHARMACEUTICALS LTD.**



**BEXIMCO  
PHARMA**

**BEXIMCO PHARMACEUTICALS LTD.**

17 Dhanmondi R/A, Road No. 2

Dhaka-1205, Bangladesh

Website : [www.beximcopharma.com](http://www.beximcopharma.com)